Press Releases

Glooko, Inc. announced the appointment of Alfonso “Chito” Zulueta, a former Eli Lilly & Company senior executive, to its Board of Directors.

Paris-based health platform provides diabetes remote monitoring and enhances physician-patient collaboration

Combined Offering Provides all the Components of an End-to-End Platform

Acquisition expands Glooko’s digital health capabilities with machine learning

Research Finds Connected Pens Significantly Reduce Missed Doses and Improves Time in Recommended Glucose Range

Glooko Inc., the leading provider of remote patient monitoring and data management platforms in diabetes and related chronic conditions, today announced the appointment of Prakash Menon as the Company’s Chief Technology Officer.

A study of the use of remote patient monitoring (RPM) with diabetes patients demonstrated improved and sustained glycemic control at 3-, 6- and 12-month intervals among people with type 2 diabetes (PWT2D). Participants remotely shared their glucose data with care teams and received remote-based coaching interventions. The data will be presented during a poster session beginning today at the 81st Scientific Sessions (virtual) of the American Diabetes Association and are sponsored by Glooko, Inc.

Glooko Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and other chronic conditions, today announced a strategic collaboration with Eli Lilly and Company for people with diabetes that use Lilly’s connected insulin pen solutions.

Glooko Inc., a leading provider of remote patient monitoring and chronic care management solutions including diabetes and obesity has raised a $30 million Series D round of funding.

Glooko AB (“Glooko” or “The Company”) today announced, in partnership with the Diabetes Technology Network (DTN)/ Association of British Clinical Diabetologists (ABCD), a new online medical education programme for clinicians who treat people with diabetes in the UK.

As Glooko continues its journey to transform digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration, today they announced the addition of Tracy Bahl and Mike Doherty as independent members of the Board of Directors to provide guidance and support to the continued growth of the business.

Together, with Sanofi’s nearly 100-year heritage in diabetes and Glooko’s leadership in remotely connecting people living with diabetes and health care professionals, the companies will collaborate to provide people with diabetes with a digital health solution* to help manage their disease under the virtual guidance of their care teams.

As part of its continued focus on delivering data enabled solutions to improve the lives of people with diabetes, Glooko, the leader in diabetes digital health, data management solutions and remote monitoring solutions, today announced the appointment of Kyle Brown as Chief Technology Officer.

Throughout this challenging time of the COVID-19 pandemic, Glooko, a leading diabetes software company that enables people with diabetes and clinicians to manage care in real-time, is committed to helping ensure the health and well-being of people with diabetes, their caregivers, and their healthcare professionals.

As part of its continued global expansion, Glooko, the leader in diabetes digital health and data management solutions, today announced the appointment of Zach Henderson as Chief Commercial Officer and Komathi Stem as Chief Operating Officer.

Glooko®, the global leader in diabetes data management, today announced it has received Privacy Shield certification from the U.S. Department of Commerce. This official recognition verifies the company has taken specific steps to ensure the protection of consumers’ personal data when transferring it from Europe to the U.S.

Glooko®, the global leader in diabetes data management, announced today that its Mountain View, California and Gothenburg, Sweden sites have received joint ISO 13485:2016 certification from accredited certification body Intertek Testing Services NA Ltd.

Glooko®, the leader in diabetes data management solutions, continues to strengthen its global position with the introduction of several new features and expanded connectivity capabilities for the diasend® by Glooko system at this week’s 55th annual meeting of the European Association for the Study of Diabetes (EASD).

Glooko®, the global leader in diabetes data management solutions, today announced the appointment of Stephen Lien as Chief Financial Officer. Lien comes to Glooko with relevant and extensive experience serving in senior leadership roles in finance and operations across a range of related industries.

Companion Medical, a leader in the development of advanced insulin delivery technology to improve diabetes care, and Glooko, a leader in diabetes data visualization and management, have announced an integrated data partnership agreement that will enable insulin data from users of the InPen™ Smart Insulin Injection Pen to be integrated into the Glooko^® Enterprise diabetes data management system and Glooko^® Mobile App. This integration, through Apple Health, will allow users to automatically integrate their insulin data with the Glooko diabetes data management system for clinical evaluation by their healthcare professionals.

​Glooko, the leader in diabetes data management solutions, today announced the appointment of Mark Clements, MD, PhD, CPI, FAAP, as Chief Medical Officer. Dr. Clements joins the senior management team of Glooko having served on its medical advisory board since it was formed in 2015 to provide expertise to the organization in the areas of clinical studies and diabetes analytics.

Glooko, the leader in diabetes data management, announced today its mobile app (available for Android and iOS) is now free* for any person with diabetes.

Glooko, the leader in diabetes data management, is gearing up for the ATTD trade show (Advanced Technologies & Treatment for Diabetes) with several exciting announcements: the launch of Novo Nordisk connected insulin pens on the diasend® platform, compatibility with the Dexcom G6 continuous glucose monitor – and the release of its Annual Diabetes Report, which will be presented to the audience in Berlin later this week.

Glooko, the leader in diabetes data management, had a successful 2018 fueled by strong growth in health system customers, international expansion, and new partnerships. The recent success creates a strong foundation for continued momentum in 2019.

Novo Nordisk today announced plans to make the durable, connected insulin pens NovoPen® 6 and NovoPen Echo® Plus commercially available across key markets commencing in early 2019. In parallel, to support the future integration of its connected pens with broader digital health solutions, Novo Nordisk has signed new partnership agreements with leading diabetes technology companies that share Novo Nordisk’s vision to improve the lives of people with diabetes: Dexcom, Glooko and Roche.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod^® Insulin Management System (Omnipod System), today announced that it has partnered with Glooko^®, Inc. to connect Insulet’s Omnipod System user data with Glooko+diasend^®, the most comprehensive diabetes data management system available, across Europe.

Glooko, the leader in diabetes data management, today announced participation in the 78th Annual American Diabetes Association (ADA) meeting taking place this weekend in Orlando, Fla.

DreaMed Diabetes, developer of personalized diabetes management solutions, announced today that the U.S Food and Drug Administration (FDA) has granted a De Novo request for DreaMed Advisor Pro, an artificial intelligence (AI)-based diabetes treatment decision support software.

Glooko, the leader in diabetes data management, today announced the delivery of a new version of the Glooko Web Application (Population Tracker) that includes streamlined navigation and a large array of diabetes analytics, charts and graphs.

(NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced a partnership with Glooko, Inc, the leading diabetes data management company.

Glooko, the leader in diabetes data management, today announced the results of its recent study which  examined diabetes healthcare professionals’ use of CGM data. The study asked 38 diabetes healthcare professionals (29 endocrinologists; nine diabetes educators) to assess CGM data from 10 people with type 1 diabetes within the Glooko platform.

(NASDAQ: VLRX), a medical technology company which offers patients with type 2 diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, announced today it has entered into an agreement with Glooko, a leader in diabetes data management.

Glooko, the leader in diabetes data management, today announced the appointment of Russ Johannesson as its new CEO. Outgoing CEO, Rick Altinger, will remain with Glooko as the Executive Vice President of Corporate Development.

Glooko, the leader in diabetes data management, today announced the results of its pilot program with Sharp Rees-Stealy Medical Group that aimed to optimize data-driven decisions for type 2 diabetes patients with high A1c levels. The six-month program revealed strong improvements in average blood glucose levels, patient adherence and engagement.

Glooko, the leader in diabetes data management, today announced its Mobile Insulin Dosing System (MIDS) has been cleared by the Food and Drug Administration for the titration of long-acting insulin for people with type 2 diabetes. Glooko’s MIDS is the first insulin titration application accessible through a unified diabetes management platform, which provides a complete program for diabetes management.

Glooko, the leader in diabetes data management, today released its annual, comprehensive diabetes report based on analysis of over 8.5 billion de-identified data points. The report observes trends based on information collected from more than 1.5 million people with diabetes (PWDs) globally and includes by-country views of glycemic trends, occurrences of hyperglycemia and hypoglycemia, and insulin usage.

Glooko, the leader in diabetes data management, today announced that recent growth in its Health System and Payer customer base is driving strong momentum for 2018 and beyond.

Glooko, the leader in diabetes data management, announced the results of a feasibility study that examined the impact of Glooko’s product, the Mobile Insulin Dosing System (MIDS) on glycemic control of people with type 2 diabetes on long acting insulin. MIDS is currently available for investigational use only.

Novo Nordisk and Glooko have announced that the new Cornerstones4Care Powered by Glooko app (C4C app) is now available to help people more effectively manage their diabetes. The C4C mobile app marries Novo Nordisk’s extensive knowledge of diabetes and personalized patient support with Glooko’s digital platform and data analytics expertise. This is the first jointly developed product from the two companies since announcing their collaboration in January 2017.

Glooko, the leader in diabetes data management, today announced $35 million in new funding to accelerate growth, expand international presence, and deepen expertise in data analytics. This round was led by Georgian Partners, a Toronto-based investor focused on applied analytics and machine learning.

Glooko, the leader in diabetes data management today announced the results of two retrospective studies that examine the clinical impact of use of its diabetes management mobile application. The studies found that using the Glooko mobile app was associated with a drop in average blood glucose, estimated A1C (eA1C) and hyperglycemia rates in people with diabetes.

Glooko, the leader in diabetes data management, today announced an expanded agreement with Dexcom, the leader in Continuous Glucose Monitoring (CGM) for people with diabetes.

Fit4D, a diabetes patient engagement solution, announced a partnership today with Glooko, a global diabetes data management company, to deliver highly personalized, data-driven coaching and a mobile health solution to patients and care providers.

Ascensia Diabetes Care and Glooko, Inc today announced a global technology partnership designed to bring together their state-of-the-art diabetes management solutions, and improve diabetes data management and analytics. This collaboration includes integration of Glooko’s Diabetes Data Management Platform and Ascensia’s CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose monitoring systems.

Novo Nordisk and Glooko today announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The non-exclusive collaboration will combine Novo Nordisk’s deep knowledge of diabetes with Glooko’s digital platform and data analytics expertise.

Glooko, the leader in diabetesremote patient monitoring, today released its annual, comprehensive diabetes data report based on over 4.3 billion deidentified diabetes data points. The data in the report includes insights derived from the combined datasets of Glooko, Inc. and Diasend.

Atrius Health has always been an innovator when it comes to providing services to their patients.

For people either living with or caring for people with diabetes, Glooko and Diasend are well-known for making diabetes management easier by offering best-in-class diabetes management and analytics platforms that facilitate data driven care for patients and clinicians.

AMC Health, the leading provider of proven remote patient monitoring and engagement solutions that are exclusively endorsed by the American Hospital Association, and Glooko Inc., the leading population health platform for diabetes management, today announced a partnership to help clinicians and patients improve diabetes outcomes at lower costs.

Glooko Inc., the leading unified platform for diabetes management, today announced compatibility with Medtronic MiniMed ® insulin pumps and sensors.

Glooko Inc., the leading unified platform for diabetes management, today announced its new ‘Glooko Advise’ product line, including ‘Glooko Personal Advisor’ and ‘Glooko Clinical Advisor,’ which enables both people with diabetes (PWDs) and clinicians with practical diabetes decision support.

Glooko, Inc., provider of the leading unified platform for diabetes management, and DreaMed Diabetes, developer of innovative and patient-centric decision support technologies for insulin-dependent people with diabetes (PWDs), today announced a partnership to commercialize DreaMed’s Advisor algorithm using the Glooko platform. The partners will demonstrate the integrated solution at the Advanced Technologies & Treatments for Diabetes (ATTD) conference, from 3 – 6 February 2016 in Milan, Italy.

Glooko, the leading unified platform for diabetes management, today  announced that Glooko was featured in a poster presentation on the effectiveness of Glooko-enabled Type 2 diabetes management resulting from a pilot conducted at the Diabetes & Glandular Disease (DGD) Clinic.

Glooko Inc., the leading unified platform for diabetes management, today announced general availability of its integration with Roche ’s Accu-Chek Aviva Connect blood glucose meters to send blood glucose (BG) results automatically to the Glooko platform. Through wireless Bluetooth Smart technology built into these Accu-Chek Aviva Connect meters, the release enables near real-time syncing of blood glucose data to the Glooko platform without the need to connect cables.

Glooko Inc., today announced the official launch of its “Glooko Office Kiosk” package, which for the first time enables diabetes data from popular blood glucose meters, insulin pumps, and continuous glucose monitors (CGMs) to be synced to an Android tablet and visualized in aggregate on Glooko’s mobile, cloud-based diabetes management platform.

​Glooko Inc​., the leading unified platform for diabetes management, today announced the formation of its first Medical Advisory Board who will provide Glooko with clinical expertise in the area of diabetes analytics and clinical studies.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced an agreement with Glooko, the trusted leader in diabetes data unification and analytics, to improve access to meaningful diabetes health data in a safe and secure way.

Glooko Inc. today announced it will demonstrate its integration with Insulin Pumps and Continuous Glucose Monitors (CGMs) at the American Diabetes Association’s 75 th Scientific Sessions , adding to the diabetes population management platform’s existing support for 30+ blood glucose meters, popular activity trackers, and biometric monitors for blood pressure and weight .

Glooko Inc. today announced partnerships with Dexcom, Inc., developer and marketer of a continuous glucose monitoring (CGM) system, and with Insulet Corporation, the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System.

Glooko Inc., the leading unified platform for diabetes management, today announced the addition of two new executives to its management team.

Glooko Inc. today announced that it has raised $16.5 Million in Series B financing. The funds will be used to expand the company’s FDA-cleared, HIPAA-compliant platform to include device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms.

Glooko Inc., announced today the launch of Glooko MeterSync Blue, strengthening its position as the industry leader in delivering a mobile, software as a service (SaaS) diabetes remote monitoring and population management platform.

Joslin Institute for Technology Translation (JITT) at Joslin Diabetes Center, the world’s preeminent institution in diabetes research and clinical care, and Glooko Inc., a mobile, cloud based diabetes management system announced the release of their jointly developed Joslin HypoMap™ powered by Glooko™.

Joslin Diabetes Center, the world’s pre 7 eminent institution in diabetes research and clinical care, and Glooko Inc. have signed an agreement to jointly deploy an advanced diabetes management technology platform that will allow patients to share diabetes management data and in turn use that data through decision 7 making algorithms for optimal and predictive diabetes care. Glooko and Joslin will jointly provide a diabetes management solution globally to health systems , governments and payer groups aiming to improve health outcomes and lower costs.

Glooko Inc., makers of a FDA-cleared mobile diabetes management system , announced today it has raised $7 million in a Series A-1 round from several new investors including Samsung Venture Investment Company (SVIC ) and Lifeforce Ventures as well as existing investors including The Social + Capital Partnership , Sundeep Madra and Yogen Dalal. Using this investment, Glooko will focus on enabling predictive diabetes care by delivering patient data and decision-making algorithms to health providers and payer groups.

Glooko, Inc., makers of an innovative mobile solution for diabetes management, today announced it has launched an Android – compatible version of its next generation Glooko Diabetes Management System .

Glooko, Inc., makers of an innovative mobile solution for diabetes management , has received FDA 510(k) clearance for its next-gen Glooko System including its Glooko iPhone application, MeterSync Cable and web dashboards for both patients and healthcare providers . In addition, the company has announced the hiring of Holly D. McGarraugh as Vice President of Business Development and Rita Sharma as Vice President of Marketing .

Glooko, Inc., makers of an innovative mobile logbook solution for people with diabetes, today announces the hiring of Rick Altinger as CEO and Dean Lucas as vice president of product development.

Glooko, Inc., makers of an innovative mobile logbook solution for people with diabetes , today formally introduces its Glooko ™ Logbook app and Glooko MeterSync Cable for iOS devices in Canada.

Glooko, Inc. , makers of an innovative mobile solution for people to log blood sugar readings, today announces Glooko ™ Logbook 1.5 for iOS devices , with new support for six additional popular blood glucose meters.

Glooko, Inc ., makers of an innovative mobile logbook solution for people with diabetes , today officially launches its Glooko™ Logbook Charts in the European Union and Glooko Logbook History Report in the US, Canada and European Union.

Glooko, Inc., makers of an innovative diabetes logbook solution, and Roche Diabetes Care, makers of ACCU-CHEK blood glucose monitoring systems, insulin pumps and information management solutions, today announced their co-promotion of the Glooko Logbook solution in the U.S .

Glooko, provider of a unique hardware device and app solution for people with diabetes, today announced a $3.5 Series A financing round, led by The Social+Capital Partnership, with participation from existing investors.